Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc daily Stock Chart
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.20 Insider Own1.00% Shs Outstand360.33M Perf Week-0.23%
Market Cap6.35B Forward P/E- EPS next Y-0.06 Insider Trans0.00% Shs Float149.51M Perf Month-9.18%
Income-63.40M PEG- EPS next Q-0.02 Inst Own54.80% Short Float30.79% Perf Quarter-15.85%
Sales363.80M P/S17.45 EPS this Y-75.40% Inst Trans2.44% Short Ratio4.66 Perf Half Y18.89%
Book/sh1.64 P/B10.74 EPS next Y50.00% ROA-12.60% Target Price30.20 Perf Year3.04%
Cash/sh1.87 P/C9.43 EPS next 5Y24.70% ROE-26.70% 52W Range13.76 - 26.12 Perf YTD-17.82%
Dividend- P/FCF- EPS past 5Y17.60% ROI-51.40% 52W High-30.36% Beta0.75
Dividend %- Quick Ratio3.50 Sales past 5Y54.10% Gross Margin77.20% 52W Low32.19% ATR0.79
Employees530 Current Ratio3.70 Sales Q/Q103.30% Oper. Margin-16.90% RSI (14)41.89 Volatility3.10% 3.84%
OptionableYes Debt/Eq0.10 EPS Q/Q88.10% Profit Margin-17.40% Rel Volume0.64 Prev Close17.62
ShortableYes LT Debt/Eq0.02 EarningsFeb 26 BMO Payout- Avg Volume9.87M Price18.19
Recom2.50 SMA20-4.52% SMA50-10.84% SMA200-0.84% Volume6,271,381 Change3.23%
Feb-18-20Upgrade Citigroup Neutral → Buy $27 → $24
Jan-06-20Initiated JP Morgan Neutral $22
Dec-16-19Downgrade Stifel Buy → Hold
Nov-20-19Initiated Oppenheimer Underperform $7
Nov-18-19Downgrade Citigroup Buy → Neutral
Nov-15-19Reiterated SVB Leerink Outperform $26 → $29
Oct-31-19Initiated Aegis Capital Buy $23
Oct-15-19Initiated Goldman Neutral $17
Aug-14-19Initiated SVB Leerink Outperform $26
Jul-09-19Reiterated Jefferies Buy $30
Jun-17-19Initiated ROTH Capital Buy $31
Mar-22-19Initiated Stifel Buy $27
Nov-14-18Upgrade Citigroup Neutral → Buy
Nov-02-18Downgrade Citigroup Buy → Neutral
Jun-27-17Resumed Cantor Fitzgerald Overweight
Oct-19-16Initiated Citigroup Buy $5
Oct-05-16Initiated Cantor Fitzgerald Buy $6
May-12-16Resumed Jefferies Buy
Mar-12-15Upgrade H.C. Wainwright Neutral → Buy $2.50 → $10
Apr-01-14Reiterated MKM Partners Neutral $1.50 → $2
Feb-18-20 08:48AM  Buy Amarin Stock Because It Has Fallen Far Enough, Analyst Says
Feb-14-20 01:44PM  Vascepa Growth Will Power Amarin Stock Way Higher in 2020 InvestorPlace
11:41AM  Risks Remain, but Amarin Stock Is a Buy at Todays Prices InvestorPlace
Feb-12-20 02:03PM  Will Positive Patent News Send Amarin Stock Higher? Analysts Fight It Out TipRanks
Feb-11-20 05:45PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-06-20 09:26PM  Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval GlobeNewswire
Feb-05-20 05:50PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-30-20 05:45PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
01:44PM  Amarin Stock's Outlook Not for the Faint of Heart
Jan-28-20 01:48PM  5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
06:30AM  HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl) CNW Group
Jan-23-20 09:31AM  A Tale of 3 Healthcare Stocks 2 to Buy, and 1 to Sell TipRanks
Jan-17-20 11:07AM  Does Acasti Stock Have a Future? InvestorPlace
06:30AM  Why Amarin Stock Is Poised for a Healthy 2020 InvestorPlace
Jan-16-20 05:37AM  Does Amarin Corporation plc's (NASDAQ:AMRN) CEO Pay Matter? Simply Wall St.
Jan-15-20 05:45PM  Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-14-20 09:46AM  AstraZeneca to End Phase III Study on Fish Oil Heart Drug Zacks
Jan-13-20 04:22PM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
02:31PM  Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint MarketWatch
11:07AM  Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short
09:40AM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
06:00AM  Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire
Jan-10-20 06:08PM  AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down Zacks -5.20%
01:02PM  Amarin Stock Bouncing Back After Revised Results and 2020 Guidance InvestorPlace
12:08PM  7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount InvestorPlace
10:59AM  All Bets Are Off for Amarin Stock InvestorPlace
08:40AM  BioMarin (BMRN) Catches Eye: Stock Jumps 5.8% Zacks
Jan-09-20 04:47PM  Applied Therapeutics Up on Positive Galactosemia Study Data Zacks
Jan-08-20 10:04AM  Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease Zacks
09:28AM  How Did Amarin Corporation plc (AMRN) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
09:00AM  Why Amarin (AMRN) Stock Might be a Great Pick Zacks
08:53AM  Amarin Posts '19 Preliminary Results, Gives 2020 Expense View Zacks
Jan-07-20 01:53PM  Amarin Corporation (AMRN): All Eyes on Vascepa 2020 Sales TipRanks -5.42%
10:55AM  Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher Zacks
09:19AM  aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma Zacks
08:45AM  Bullish Looking Amarin Is Set to More Than Double From Current Levels
06:37AM  Amarin raises 2019 revenue outlook, to double sales team as it 'aggressively' launches Vascepa in the U.S. MarketWatch
06:00AM  Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire
Jan-06-20 05:50PM  Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know Zacks
03:30PM  HLS Therapeutics Announces 8 Years of Data Protection for Vascepa® CNW Group
09:03AM  Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
06:00AM  Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-20 06:00AM  Amarin Risks Getting Exposed as a Paper Tiger InvestorPlace
Jan-02-20 09:16AM  Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day Zacks
08:46AM  The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga
06:00AM  VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire
Dec-31-19 01:00PM  HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events CNW Group
12:01PM  Vascepas Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock InvestorPlace
09:35AM  Health for Patients, Wealth for Investors: Watch Amarin Stock Closely InvestorPlace
08:45AM  3 Biotech Stocks Likely to Maintain Solid Momentum in 2020 Zacks
08:22AM  Heres Why Amarin Stock Slumped Despite the FDA Approval InvestorPlace
Dec-27-19 11:30AM  Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year? Zacks
Dec-24-19 07:30AM  10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-21-19 11:08AM  Amarins fish-oil pill is now available to millions more patients, but its still no Lipitor MarketWatch
Dec-20-19 04:41AM  Amarin Stock is at Sky-High Levels Already Assumes All the Good News InvestorPlace
Dec-19-19 12:00PM  Amarin (AMRN) is a Great Momentum Stock: Should You Buy? Zacks
10:13AM  The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
Dec-18-19 02:27PM  Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-17-19 07:56AM  The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga -6.73%
Dec-16-19 02:28PM  Analyst: With FDA Approval Already Priced In, Avoid Amarin (AMRN) Stock TipRanks -5.14%
01:38PM  Amarins Vascepa Approval Seems Fishy for Patients and AMRN Investors InvestorPlace
09:58AM  Dow Jones Today Rallies, Goldman Up, Boeing Down; Amarin Scores A Breakout Investor's Business Daily
09:37AM  After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target Benzinga
08:47AM  Fish Oil-Derived Heart Drug Wins at the FDA. Amarin Stock Is Soaring.
08:38AM  Amarin Gains on FDA Approval of Vascepa Label Expansion Zacks
08:15AM  Dow Jones Futures: After China Trade Deal, Which Sectors Will Lead Stock Market Rally? Investor's Business Daily
Dec-14-19 12:57PM  Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval MarketWatch
Dec-13-19 07:41PM  This Biotech Stock Just Got A Highly Anticipated FDA Approval Investor's Business Daily
06:14PM  Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk PR Newswire
05:34PM  Amarin gets FDA approval for new Vascepa use, U.S. shares gain in late trading MarketWatch
04:49PM  Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk GlobeNewswire
03:48PM  Amarin Has the Makings for a Gamechanging Product InvestorPlace
Dec-11-19 11:30AM  Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year? Zacks
Dec-09-19 09:18AM  All Eyes on These 3 Biotech Stocks Ahead of FDA Decisions TipRanks
Dec-06-19 06:40AM  Acquisition Rumors Arent the Only Thing Moving Amarin Stock InvestorPlace
Dec-03-19 04:51PM  These Hedge Funds Cashed Out Of Amarin Corporation plc (AMRN) Too Early Insider Monkey
12:00PM  Amarin (AMRN) is a Great Momentum Stock: Should You Buy? Zacks
09:16AM  Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU Zacks
Dec-02-19 09:21AM  Do Options Traders Know Something About Amarin (AMRN) Stock We Don't? Zacks
07:00AM  Heart Drugs Are Having a Moment Bloomberg
06:00AM  European Medicines Agency Accepts for Review Marketing Authorization Application for Amarins Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® Study GlobeNewswire
05:26AM  Amarin Corporation plc's (NASDAQ:AMRN) Shift From Loss To Profit Simply Wall St.
Nov-27-19 05:27PM  Why A Stock Market Correction Would Be A Good Thing Right Now: Advisor Investor's Business Daily
08:03AM  Top Ranked Momentum Stocks to Buy for November 27th Zacks
Nov-26-19 12:20PM  Why Did Farallon Capital Get Out of These 3 Biotech Stocks? TipRanks
Nov-21-19 08:23AM  Amarin's Shares Down on Underperform Rating by Oppenheimer Zacks
Nov-20-19 01:28PM  Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks TipRanks -10.87%
10:14AM  Amarin shares fall 10% on analyst concerns about growth MarketWatch
10:12AM  Amarin Stock Is Sinking After a Bearish Assessment of Its Heart Drug
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
Nov-19-19 06:27PM  Oppenheimer Sees Doom and Gloom in Amarin (AMRN) Stock TipRanks
Nov-18-19 07:52PM  Edited Transcript of AMRN earnings conference call or presentation 5-Nov-19 12:30pm GMT Thomson Reuters StreetEvents -5.91%
05:30PM  Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions GlobeNewswire
05:27PM  How Much Higher Can Amarin (AMRN) Stock Go Following FDA Approval? TipRanks
12:15PM  Amarins John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award GlobeNewswire
10:29AM  Matinas Rides Amarin's Coattails as Vascepa Wins FDA Panel Vote
08:41AM  Amarin Stock Has Soared. Citi Thinks Its Gone Far Enough.
06:42AM  Will Amarin Continue to Surge Higher? Zacks
Nov-15-19 04:32PM  This Biotech Stock Broke Out Bullishly On A Key FDA Recommendation Investor's Business Daily +11.77%
03:04PM  Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated Benzinga
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Biologix FZCo, and HLS Therapeutics, Inc. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.